Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9987234 | 0.84 | TDP1 (0.61) | MAPK1POLBCES1KMT2AMEN1 | |
| SCHEMBL12239770 | 0.83 | POLB (0.50) | MAPK1POLBCES1KMT2AMEN1 | |
| SCHEMBL15058771 | 0.83 | PPARG (0.50) | MAPK1POLBCES1KMT2AMEN1 | |
| SCHEMBL17203013 | 0.83 | KMT2A (0.55) | MAPK1KMT2AMEN1NR1H4ALDH1A1 | |
| SCHEMBL109451 | 0.82 | CA1 (0.61) | MAPK1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL8137824 | 0.82 | SMN1; SMN2 (0.52) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL31270988 | 0.82 | ALOX5 (0.53) | CES1KMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL12546685 | 0.81 | ALDH1A1 (0.45) | MAPK1POLBCES1KMT2AMEN1 | |
| SCHEMBL8110956 | 0.81 | POLB (0.49) | MAPK1POLBKMT2AMEN1CA1 | |
| SCHEMBL294244 | 0.80 | MAPK1 (0.50) | MAPK1POLBCES1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117279905-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116847885-A | Dual cleavage ester linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | of Queen Elizabeth near Dublin | 2012-04-19 | — | — | US | disclosed |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | of Queen Elizabeth near Dublin | 2012-04-19 | — | — | US | disclosed |
| WO-2010072734-A2 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-7357291-B2 | Solder metal, soldering flux and solder paste | SHOWA DENKO K.K. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-6881278-B2 | Flux for solder paste | SHOWA DENKO K.K. (JP) | 2005-04-19 | — | — | US | disclosed |
| EP-1367046-A9 | Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1367046-A1 | Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030200836-A1 | Flux for solder paste | SHOWA DENKO K.K. | 2003-10-30 | — | — | US | disclosed |
| US-20020046627-A1 | Solder powder, flux, solder paste, soldering method, soldered circuit board, and soldered joint product | SHOWA DENKO K.K. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-20010042779-A1 | Solder paste | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2001-11-22 | — | — | US | disclosed |
| EP-1060160-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999043636-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-02 | — | — | WO | disclosed |
| CN-1175259-A | Low molecular weight bicyclic thrombin inhibitors | IAF BIOCHEM INT (CA) | 1998-03-04 | — | — | CN | disclosed |
| US-4219482-A | Process for preparing thiophene and furan derivatives | LABAZ (FR) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | PTGS2, SI, PTGS1 | MAPK1 1956/4885POLB 2806/4885CES1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.